Safusidenib Phase 2 Study in IDH1 Mutant Glioma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT05303519 |
|
Recruitment Status :
Recruiting
First Posted : March 31, 2022
Last Update Posted : November 14, 2023
|
Sponsor:
AnHeart Therapeutics Inc.
Information provided by (Responsible Party):
AnHeart Therapeutics Inc.
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | March 31, 2027 |
| Estimated Study Completion Date : | July 31, 2027 |